Oltipraz is a synthetic dithiolethione with an antisteatotic effect by inhibiting the activity of liver X receptor alpha (LXR-a). Recent studies demonstrated the disruptive role of oltipraz on LXR-a-dependent lipogenesis in hepatocytes and a high-fat diet mouse model.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a common condition characterised by the accumulation of fat in the liver, ranging from simple steatosis to steatohepatitis. [1] [2] [3] [4] Although the exact mechanism by which steatosis evolves into non-alcoholic steatohepatitis (NASH) has not yet been elucidated, the excessive accumulation of intrahepatic fat rather than visceral fat seems to play a primary role in the pathogenesis of NAFLD, which is also implicated in the development of complications of metabolic syndrome. 5 According to the third National Health and Nutrition Examination Survey, the prevalence of ultrasonographydiagnosed NAFLD was 34% and that of advanced fibrosis was 3.2% in the general United States population. 6 Only a minority of people with NAFLD develop NASH, which is characterised by inflammation and scarring of the liver, and 9-20% of NASH cases might progress to cirrhosis. 7 Those with NAFLD are at risk of death resulting from liver failure or hepatocellular carcinoma as well as cardiovascular events. 6 Recently, the magnetic resonance imaging (MRI)-determined proton density fat fraction (PDFF) technique as well as magnetic resonance (MR) spectroscopy (MRS) has enabled to perform non-invasive quantitative analysis of liver fat content. MRS can accurately assess the liver fat content by calculating the amounts of intrahepatic triglycerides (TGs) with a difference in the resonance frequencies between water and fat proton signals within the liver. 8, 9 Thus, both MRI-PDFF and MRS may be reliably used as an alternative to liver biopsy to evaluate the efficacy of novel pharmacological therapies against NAFLD in short term, proof-of-concept trials. [10] [11] [12] [13] Although the epidemiologic data have revealed a sharp rise in the prevalence of NAFLD with the global epidemic of obesity, no proven therapeutic measures against NAFLD have been established yet. Recent trends in the treatment of NAFLD focus on nonpharmacological interventions to correct metabolic risk factors. In addition, vitamin E as an antioxidant may be beneficial in nondiabetic patients with NAFLD and thiazolidinediones (TZDs) as an insulin sensitizer may be effective for the histological improvement in those with NAFLD. 14, 15 However, given the potential adverse effects, the longterm safety of vitamin E and TZDs deserves further investigation, and exploration of new therapeutic agents against NAFLD is challenging.
Adenosine monophosphate activated protein kinase (AMPK) is a serine/threonine kinase that plays a crucial role in the regulation of carbohydrate and fat metabolism. 16 The activation of AMPK depletes the pool of malonyl-coenzyme (Co)-A through the inhibition of acetyl CoA carboxylase-1 (ACC), leading to the increment in fatty acid oxidation and decrement of fatty acid synthesis within the liver. 16 AMPK may modulate liver X receptor alpha (LXR-a) activity and decrease the expression of sterol regulatory element binding protein 1c (SREBP-1c), a key regulatory factor of lipid production which is increased in patients with NAFLD. Simultaneously, the increased expression of fatty acid synthase, ACC, and stearoyl-CoA desaturase-1 (SCD-1) may also contribute to the enhancement of hepatic lipogenesis. 17 Oltipraz, 5-(2-pyrazynyl)-4-methyl-1,2-dithiole-3-thione, is a synthetic dithiolethione that functions as an antisteatotic agent against NAFLD by inhibiting LXR-a activity. 18 Mechanistically, oltipraz possesses a therapeutic potential for the amelioration of steatosis by activating AMPK and inactivating S6K1 alternately. Oltipraz in turn reduces the synthesis of fatty acid but expedites lipid oxidation by inhibiting the LXR-a activity and decreasing the expression of SREBP-1c within the liver. 18 Hence, we attempted to evaluate the antisteatotic efficacy and safety of oltipraz to improve fatty liver and to obtain information on the population pharmacokinetics in subjects with NAFLD.
METHODS

Study population
We screened patients with fatty liver using liver ultrasonography. Subjects with NAFLD were prospectively enrolled according to the following inclusion criteria. The inclusion criteria were aged ≥20 or <75 years; liver fat content >20% with an MRS within 3 months of screening; alcohol consumption <40 g/week; two consecutive results of the serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level >39 IU/ L (the upper limit of normal range) within 2 weeks of screening; haemoglobin ≥13 mg/dL (male) or ≥12 mg/dL (female); and females who agree to using contraceptive precautions. The exclusion criteria are presented in method 1 in Data S1.
Study design
We conducted a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase II study to evaluate the efficacy, safety and pharmacokinetics of oltipraz in patients with NAFLD without cirrhosis. The study was conducted at five university-affiliated hospitals in Korea. Study subjects were randomly assigned, in a 1:1:1 ratio, to receive either oltipraz (Pharmaking Co., Ltd, Seongnam, Korea) (30 mg or 60 mg) or placebo twice daily within 1 h after meals for 24 weeks, and they were blinded to treatment. Block randomization was used to allocate at least 20 subjects per group (placebo, 60 mg/ day or 120 mg/day oltipraz). The dietitian at each site instructed all participants to keep a low-fat hypocaloric diet by reducing their intake by 500 kcal/day. This study was conducted in agreement with Good Clinical Practice and the Declaration of Helsinki, and it was approved by each hospital's institutional review board (NCT01373554). Written informed consent was obtained from all subjects. We complied with the CONSORT statement for reporting randomised trials ( Figure S1 ).
Sample size determination
In a previous study, there was a 10% reduction in the liver fat content from baseline to week 24 in the pioglitazone-treated group, while there was no difference (0%) in the placebo-treated group. 15 In another study, there was a 4.6% reduction in the liver fat content in a group in which 8% of the weight loss was attained by dietary modification. 19 We hypothesised that a 10%, 4.6% and 0% reduction in the liver fat content would be attainable in the high-dose (120 mg/day of oltipraz), low-dose (60 mg/day of oltipraz) and placebo groups. Since NASH is often accompanied by type 2 diabetes, 20 we pooled the s.d. of liver fat content at baseline from pioglitazonetreated NAFLD or type 2 diabetic patients. 15, 19, 21, 22 The greatest s.d. (4.2%) estimated for the change in the liver fat content and the smaller difference (4.6% in the low-dose and placebo groups) of the change in the liver fat content between groups were chosen to estimate the sample size conservatively. Thus, a sample size of at least 20 subjects per group was required to detect a difference in the change in the liver fat content between groups using standard statistical criteria (a statistical power, 0.9; level of significance for a two-tailed test, 0.05; and dropout rate, 10%).
Efficacy assessment
The full analysis set (FAS) was composed of subjects who received the study medication at least once among all the randomised subjects and then underwent measurements of primary efficacy at baseline and at the end of treatment. The per-protocol set (PPS) was composed of those who completed this study, according to the protocol, without major protocol violation, noncompliance 
Pharmacokinetic assessment
The first blood sample per subject was collected prior to the study drug administration at baseline. Then, the three blood samples were sequentially collected at week 8 after checking whether the subject had missed any dose during the last 3 days prior to sampling. The second blood sample was collected within 5 min prior to study drug administration to determine the trough level. In addition, more than two blood samples were taken 2-5 h after study drug administration at intervals of >2 h. The final population pharmacokinetics model was constructed by serially measuring the plasma concentrations of oltipraz and active metabolite (M2) before and after administering 30 mg or 60 mg of olitpraz twice daily for 8 weeks. 23, 24 Diagnostics of the final pharmacokinetics model of oltipraz and M2 were made using basic goodness-of-fit plots and visual predictive check (VPC) plots.
Statistical analysis
The efficacy outcomes were assessed according to the intention-to-treat principle. Thus, the primary efficacy was evaluated in the FAS population. We employed the last-observation-carried-forward approach for analysing subjects with missing data. The primary and secondary efficacy analyses were performed using the two-sample ttest or Wilcoxon's rank sum test according to the normal distribution of variables analysed. A paired t-test was used for testing changes within the treatment groups in continuous parameters. We also used repeated measure analysis of variance to determine the time trend of efficacy variables. The safety data for all subjects who received at least one dose of the study medication were summarised according to the actual treatment dosage. Categorical data such as differences in the incidence of adverse events among the groups were analysed using Pearson's chi-square or Fisher's exact tests according to the normal distribution of variables analysed. A twotailed P <0.05 was considered statistically significant using SAS, version 9.1.3 (SAS Institute, Cary, NC, USA).
The population pharmacokinetic analysis of oltipraz and M2 was performed based on a nonlinear mixed effect model using NONMEM software, version 6.2 (Icon Development Solutions, Ellicott City, MD, USA) using a pooled pharmacokinetic method.
RESULTS
Subjects' disposition and baseline characteristics
We screened 130 subjects with NAFLD between May 2011 and June 2013. Sixty-two were excluded: 51 did not fulfil the inclusion criteria, 10 declined participation, and one was excluded for other reasons. The remaining 68 subjects were randomised. Finally, 64 were given a placebo (n = 21), 60 mg/day (n = 21) of oltipraz or 120 mg/day (n = 22) of oltipraz in the FAS after excluding four subjects who experienced failure to undergo follow-up MRS at the end of treatment ( Figure S1 ). Of 64 subjects, 50 (78%) completed the study and were included in the PPS. Twelve were prematurely withdrawn because of the following reasons: erratic inclusion of study subjects with a major violation in the eligibility criteria (n = 6), dropped-out due to noncompliance (administration of <70% of the study drug) due to adverse drug reactions (n = 5), and received epidural steroid injections for palliation of back pain resulting from preexisting lumbar spinal stenosis (n = 1). Of the 64 included in the FAS, three (low-dose, 2; high-dose, 1) had diabetes and took only sulfonylurea without any other insulin sensitiser or insulin injection. Table 1 compares the baseline demographic, metabolic and biochemical characteristics among the three treatment groups. The three groups had well-balanced baseline characteristics except liver fat content quantified using MRS (P = 0.02).
Primary Outcomes
The absolute liver fat amount was reduced in a doseresponse manner following oltipraz treatment (FAS, placebo, À3.2 AE 11.1%; low-dose, À7.7 AE 7.0%; and highdose, À13.9 AE 10.7%; placebo vs. high-dose, P = 0.005). Individual patient data on changes in the absolute liver fat content stratified by the treatment group are presented in Figure 1 , showing a different pattern of the temporal changes of the absolute liver fat content, predominantly decreases in the low-dose and high-dose groups. To adjust for the variation in baseline liver fat content for individual subjects, we compared per cent changes in the liver fat content by dividing the difference between baseline and week 24 by baseline liver fat content. The per cent change in the liver fat content was negligible in the placebo group and was modest in the low-dose group (FAS, À0.6 AE 62.9% vs. À24.4 AE 7.0%, P = 0.12); however, it was significantly greater in the high-dose group compared to the placebo group (FAS, À34.6 AE 29.4% vs. À0.6 AE 62.9%, P = 0.046; Figure 2 ). In the PPS, the per cent change in the liver fat content was not significantly different between the high-dose and placebo groups (À35.7 AE 29.1% vs. À15.9 AE 26.5%, P = 0.06). Collectively, a high-dose of oltipraz significantly reduced the liver fat content in subjects with NAFLD, whereas a low-dose showed only modest efficacy compared to the placebo.
Secondary outcomes
Similar to the liver fat content, BMI also significantly decreased in the high-dose group, compared to the placebo group (P = 0.04; Table 2 ). However, absolute changes in insulin resistance, lipid profiles, and proinflammatory cytokines including TNF-a, IL-6, resistin, leptin and adiponectin were not significantly different among the groups. Based on the liver biochemistries, absolute changes in the ALT and AST were greater in the high-dose group than the placebo and low-dose groups; however, no significant difference was observed among the three groups. The total cholesterol and HDLcholesterol increased significantly from baseline to 24-week treatment in the low-dose group compared to the placebo group (P < 0.05 for total cholesterol, P = 0.04 for HDL-cholesterol; Table 2 ). We charted the temporal progress of each variable over 24 weeks among the 3 groups (Table S1 and Figure S2 ). Temporal changes within subjects were statistically significant for the ALT, AST, BMI, HOMA-IR and HDL-cholesterol (P < 0.05; Table S1 and Figure 3a -e). Serial data for IL-6 showed marginal significance (P = 0.06; Table S1 and Figure 3f ).
The serum adiponectin levels decreased gradually in the placebo group but increased from baseline to week 16 in the high-dose group, although this was not statistically significant (P = 0.28 between subjects; Table S1 ).
Pharmacokinetics
Briefly, 44 subjects (low-dose group, 22; and high-dose group, 22) participated in a pharmacokinetics study. The pharmacokinetic parameters of oltipraz and M2, including the maximum plasma concentration, time of maximum concentration and elimination half-life, are presented (Table S2 ). The estimates of pharmacokinetic parameters and relative standard errors in the final population pharmacokinetics model are presented (Table S3 ). The pharmacokinetic parameters accounting for interindividual variability were apparent oral clearance (CL/F) and an oltipraz to M2 rate constant (k 24 ). The body weight and single dose were significant covariates related to the CL/F of oltipraz, while no covariates were significantly associated with k 24 .
The structural models of the pharmacokinetics of oltipraz and M2 were internally validated using basic goodness-of-fit plots ( Figure S2 and S3) . Correlations between the observed values and the individual and population prediction, those between the individual weighted residuals and individual prediction, and those between the conditional weighted residuals and time after dose were analysed. No apparent deviations were noticed at any predefined concentration of the study drug or any specific time point in the residual and structural models. The final pharmacokinetics models for oltipraz and M2 were also validated using VPC plots ( Figure S4 ). A VPC that estimated the plasma concentration prediction intervals and graphically superimposed these intervals on observed concentrations after administering standardised doses (30 mg and 60 mg) was used to evaluate how well the model predicted the distribution of observed oltipraz and M2 concentrations. The VPC plot validated the adequacy of model predictions, confirming no apparent deviations between the model and observed data. The median with a 90% confidence interval for observed values lied within the predicted intervals obtained by simulation. Antisteatotic responders to oltipraz were defined as subjects who showed any degree of absolute reduction in the liver fat content from baseline to week 24, while nonresponders were defined as those who did not respond to oltipraz without any degree of reduction in the liver fat content after 24 weeks of treatment. For responders, the plasma concentrations of oltipraz, M2, or a combination of both correlated significantly with the degree of absolute reduction in the liver fat content (oltipraz, r = 0.35, P = 0.02; M2, r = 0.46, P = 0.002; and oltipraz+M2, r = 0.41, P = 0.006; Figure S5 ). However, no significant correlations were found in nonresponders. Oltipraz 60 mg/day, n = 21
Oltipraz 120 mg/day, n = 22 P = 0.046 
Safety analysis
The adverse drug reactions during the study period are summarised in Table S4 . Gastrointestinal symptoms or disorders were most frequently encountered; however, the incidence of adverse drug reactions was comparable among the three treatment groups (placebo, 11/22; low-dose, 12/22; and high-dose, 12/24). Similarly, neither the incidence of treatment-emergent adverse events nor that of adverse events causing study withdrawal was significantly different among the groups (Table S5 ). Serious adverse events, which were considered unrelated to the study drug, occurred in two subjects: a meniscus tear in the low-dose group and pneumonia in the high-dose group. Both subjects recovered completely after hospitalisation. Two subjects from the high-dose group with adverse events causing study withdrawal did not receive the follow-up MRS evaluation. One had pneumonia and the other had severe nausea, vomiting and a headache after taking a high-dose of oltipraz.
DISCUSSION
In this study, 24-week treatment with oltipraz significantly reduced the liver fat content in Asian patients with NAFLD. Moreover, its antisteatotic efficacy based on the intrahepatic TG amounts existed in a doseresponse fashion with an increase in the dose of oltipraz. Overall, we demonstrated that oltipraz has a prominent antisteatotic efficacy without incurring significant adverse events compared to a placebo. Lifestyle modification is the therapeutic cornerstone for ameliorating clinical or histological outcomes in patients with NAFLD. 25, 26 However, some patients do not fully comply with dietary recommendations or exercise because of failure in appetite control or immobilization due to morbid obesity or physical disability. In this study, there was striking evidence of a BMI-reducing efficacy after the administration of a high-dose of oltipraz, which suppressed the accumulation of liver fat. Thus, those intolerant or refractory to lifestyle modification may benefit from this novel LXR modulation therapy, as it can reduce their BMI or intrahepatic fat. The underlying basis of reducing BMI by oltipraz treatment may be associated, in part, with the M2 effect on mitochondrial biogenesis and fuel oxidation. 27 However, the exact mechanism in humans remains unclear. Weight loss per se in the high-dose group may have improved steatosis, as assessed by MRS, independent of the drug effect because the significant decrease in the BMI was apparent in the high-dose group compared to the placebo group. Regardless, this finding must be explored in further larger-scale studies.
In this study, a high-dose of oltipraz significantly reduced the liver fat content, although no significant changes in insulin sensitivity or adipokine levels were found. However, insulin resistance was measured by HOMA-IR, which is generally used in large-scale population-based studies. The hyperinsulinemic euglycaemic clamp method may be more accurate than HOMA-IR for assessing hepatic insulin resistance. 28 Nevertheless, oltipraz uniquely exhibited an excellent antisteatotic efficacy by inhibiting the hepatic lipogenic signalling pathway independent of insulin resistance or adipokine regulation.
In this study, we included subjects with NAFLD primarily based on the liver fat content according to previous literature. 15, 20, 21 Although NAFLD is usually defined as >5% of the intrahepatic fat using MRS quantification, previous studies proving an antisteatotic efficacy of pioglitazone in subjects with NAFLD consistently indicated that the cut-off value of 20% might be sufficient for the histological criteria of NASH. 15, 20, 21 Given that this study was a short-term phase II trial, we adopted a recuperation of steatosis as determined by MRS as a primary endpoint. 13 Indeed, the improvement of steatosis was accompanied by sustained improvement in ALT following oltipraz treatment, although changes in the ALT levels were not significantly different among treatment groups. Intriguingly, of the secondary outcome variables, only HDLcholesterol showed a significant change between or within subjects. Thus, oltipraz may maintain an antisteatotic efficacy by altering lipid metabolism and enhancing the HDL-cholesterol levels in subjects with NAFLD. Further studies are needed to elucidate a mechanistic link between LXR modulation and lipid metabolism. Given the recent technical advances in water-fat separation MRI, [29] [30] [31] [32] the diagnostic use of MRI-PDFF has been reliably demonstrated in several NAFLD drug efficacy studies. [10] [11] [12] The use of MRI-PDFF instead of MRS may be more advantageous because it can provide the liver fat content from whole liver mapping. However, in a multi-centre study involving different MR systems (e.g. field strength, vendordependent and/or software version-dependent pulse sequence designs, water-fat separation strategies and data post-processing tools), MRI-PDFF may be more subject to potential variable performance among research centres than MRS. For its relative simplicity in acquisition and post-processing of data, we decided to use MRS for liver fat content estimation, which is frequently used to validate MRI-PDFF findings.
10-12, 33
Under certain circumstances, it may be ideal to use both MRI-PDFF and MRS, as previously reported by the cross-validation studies between the two methods.
10-12
The main limitations of this study include some doubt on the utility of oltipraz in other ethnic populations, uncertainty about its antifibrotic effect, and the failure of the randomization which has not been performed centrally but locally in each participating centre. Indeed, the prevalence of NAFLD in a non-obese population is common in Asian countries where the individuals are less obese in general than those in Western countries. 34, 35 Accordingly, the antisteatotic efficacy of oltipraz should be obviously tested in other ethnic populations with NAFLD. Complete reversal of steatohepatitis and substantial improvement in fibrosis are reasonable surrogates for preventing cirrhosis and liver-related death. 13, 36 Generally, fibrosis progresses or regresses slowly over years in subjects with NAFLD. However, this study duration might not be sufficient to prove an antifibrotic efficacy of oltipraz or to define the rebound effect after discontinuing oltipraz. Accordingly, further larger-scale studies that use liver biopsy and noninvasive fibrosis tests such as novel serum biomarkers and MR elastography are warranted to reveal the antifibrotic effect of oltipraz. In addition, the randomization failed in terms of the significant difference in baseline liver fat content between the high-dose vs. placebo/low-dose groups, which might bias the results of this study due to the regression to the mean phenomenon or residual confounding effect. Finally, strict inclusion criteria such as the liver fat content >20% and an increased transaminases level may reduce the generalizability of the study results in terms of enrichment of the study population. Twenty-four-week treatment with oltipraz significantly reduced the liver fat content in Asian patients with NAFLD, and these findings support the disruptive role of a synthetic dithiolethione on LXR-a-dependent lipogenesis in the liver. Therefore, this provides new insight into the management of NAFLD by putting the antisteatotic role of dithiolethione into perspective (NCT01373554).
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